Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raed Alroughani

Showing results (111-120 of 223) with videos related to

Pageof 23
Sort By:
Multiple Sclerosis International|January 13, 2017
Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus RisksRaed Alroughani, Ayse Altintas, Mohammed Al Jumah, et al.
Multiple Sclerosis and Related Disorders|May 30, 2018
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]Yara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Multiple Sclerosis and Related Disorders|February 6, 2023
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activityTim Spelman, Dana Horakova, Serkan Ozakbas, et al.
Multiple Sclerosis and Related Disorders|November 29, 2017
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodYara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Therapeutic Advances in Neurological Disorders|February 28, 2024
Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapiesHelmut Butzkueven, Tomas Kalincik, Francesco Patti, et al.
Journal of the Neurological Sciences|August 15, 2018
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapyIlya Kister, Tim Spelman, Francesco Patti, et al.
Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2025
Disease course after pregnancy in women with progressive multiple sclerosis symptomsJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 19, 2024
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase RegistryAlessio Signori, Marta Ponzano, Tomas Kalincik, et al.
Pageof 23

Showing results (111-120 of 223) with videos related to

Sort By:
Pageof 23
Multiple Sclerosis International|January 13, 2017
Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus RisksRaed Alroughani, Ayse Altintas, Mohammed Al Jumah, et al.
Multiple Sclerosis and Related Disorders|May 30, 2018
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]Yara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Multiple Sclerosis and Related Disorders|February 6, 2023
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activityTim Spelman, Dana Horakova, Serkan Ozakbas, et al.
Multiple Sclerosis and Related Disorders|November 29, 2017
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodYara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Therapeutic Advances in Neurological Disorders|February 28, 2024
Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapiesHelmut Butzkueven, Tomas Kalincik, Francesco Patti, et al.
Journal of the Neurological Sciences|August 15, 2018
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapyIlya Kister, Tim Spelman, Francesco Patti, et al.
Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2025
Disease course after pregnancy in women with progressive multiple sclerosis symptomsJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 19, 2024
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase RegistryAlessio Signori, Marta Ponzano, Tomas Kalincik, et al.
Pageof 23